At follow-up , STP patients had had a lower incidence of the primary endpoint , relative to controls ( 21/49 vs. 35/45 patients ; p = 0.0006 , respectively ; NNT = 3 ) ; this benefit was attributable to the lower incidence of recurrent angina and of new comorbidities in the STP group ( 14/49 vs. 22/45 patients , p = 0.04 , NNT = 5 ; and 5/49 vs. 25/45 , p < 0.0001 , NNT = 3 , respectively ) .